

Strong quarterly growth underpins 212% increase in medicinal cannabis product sales during FY2021

- **12,187 Bod's medicinal cannabis product units sold during FY2021 – a 212% increase on FY2020 (FY2020: 3,907)**
- **17% quarter on quarter growth achieved during Q4 FY2021 with 4,441 medicinal cannabis product units sold (Q3 FY2021: 3,805)**
- **46% market share of total Australian market for full plant high CBD products retained during FY2021ⁱ**
- **65% of prescriptions filled during FY2021 were repeat patients – highlighting the quality of the Company's medicine and continued product satisfaction amongst patients and physicians**
- **Growth underpinned by ongoing educational initiatives and nationwide trials into indication specific treatments including pain and mental health issues.**
- **16,267 medicinal cannabis units since first prescriptions in 2019 – upwards trajectory expected to continue following scale up of UK operations and new product launches**

Sydney, Australia – 1 July 2021: Medicinal Cannabis, CBD and hemp healthcare products company, Bod Australia Limited ("Bod", or "the Company") (ASX: BDA) is pleased to advise that it has achieved record medicinal cannabis sales growth during FY2021. During the period, Bod dispensed a total of 12,187 products, which marks a 212% increase on the previous corresponding period (FY2020: 3,907). The Company also realised 17% quarter on quarter growth during Q4 FY2021, following the sale of 4,441 units (Q3 FY2021: 3,805).

In a major achievement, Bod retained 46% share of the total Australian market for full plant high CBD products during FY2021ⁱ, which increased during the last six months of the period. Pleasingly, 65% of prescriptions sold during FY2021 were repeat prescriptions, which highlights the medicines quality and the ongoing satisfaction and benefits both patients and physicians are witnessing with the use of Bod's medicinal cannabis products on a range of conditions.

The significant growth in prescription volumes was supported by the Company's ongoing educational initiatives with healthcare professionals, as well as Bod's nation-wide clinical study investigating the efficacy of Bod's medicinal cannabis products when prescribed for debilitating conditions including anxiety, insomnia and Post Traumatic Stress Disorder (refer ASX announcement: 16 July 2020).

Bod has now sold a total of 16,267 medicinal cannabis product units since first prescriptions in 2019 and expects to continue its strong growth over the coming months and beyond. Medicinal cannabis sales will materially add to the Company's revenue profile. Bod is continuing to scale up operations across Australia and the United Kingdom to underpin its upward trajectory and increase overall market share.




Image one: Quarterly medicinal cannabis product sales by unit during FY2021

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue 105.8m
 Market Capitalisation ~\$36m

BOARD & MANAGEMENT

Mr Mark Masterson
 Non-Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Akash Bedi
 Non-Executive Director

Mr George Livery
 Non-Executive Director

Mr Patrice Malard
 Non-Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

CEO Jo Patterson said: “Bod continues to achieve a very strong upward trajectory through its medicinal cannabis operations on both a quarter on quarter and a year on year basis. These sales will further contribute to the Company’s growing revenue profile.

“During FY2021, the Company maintained nearly a 50% market share for the total addressable market for high CBD products in Australia. While repeat prescriptions remained at a high level, Bod also increased its patient and doctor acquisitions through ongoing educational initiatives and its relationships with approved prescribers.

“We anticipate increased demand for our medicinal cannabis product suite over the coming quarter and beyond. A number of new products are currently being introduced and operations in the UK continue to scale pleasingly. We look forward to updating shareholders on further growth as it materialises.”




Image two: Cumulative medicinal cannabis product sold since June 2019

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

This announcement was authorised for release by the Board of Directors of Bod Australia Limited.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

¹ Data available until and inclusive of May 2021